Relatively few kidney patients need to start dialysis after undergoing TAVR

October 16, 2017, American College of Cardiology

The rate of patients with chronic kidney disease undergoing a heart procedure called transcatheter aortic valve replacement (TAVR) who eventually need to start dialysis is relatively low, suggests a new study published in JACC: Cardiovascular Interventions.

The findings will help physicians and with chronic kidney make more informed decisions about whether patients are good candidates for TAVR, said lead researcher James W. Hansen, DO, structural interventional cardiology fellow at the Lahey Hospital and Medical Center in Burlington, Massachusetts.

"Some patients are adamant that they do not want to go on . Now doctors will be better able to answer the question of their risk of dialysis if they undergo ," he said.

For patients who previously may not have been considered good candidates for TAVR because of their underlying kidney disease, the new findings may allow doctors to be more aggressive with their care.

"Kidneys are often a marker for a patient's overall health," Hansen said. "Chronic kidney disease is a risk factor for heart disease, and developing chronic kidney disease is often secondary to many other diseases that are related to heart disease, such as high blood pressure and poorly controlled diabetes. Many of these patients have aortic stenosis, which requires a replacement."

TAVR is a minimally invasive surgical procedure that repairs the aortic valve without removing the damaged valve. Instead, a catheter is used to deliver a replacement valve to the site of the old valve where the new valve begins regulating blood flow. It is generally reserved for patients whose poor health makes an open-heart valve replacement too risky.

The study, using data from the Society of Thoracic Surgeons/American College of Cardiology TVT Registry, included 44,778 patients who underwent TAVR from November 2011 through September 2015. Patients were organized into groups according to stage of chronic kidney disease; combined stages 1 and 2 (the least severe) served as a control group. The stages of kidney disease are measured by how much blood can be filtered by the kidney in a given period of time. None of the patients were on dialysis at the start of the study.

The researchers found that among patients with stage 3 chronic kidney disease, 2.2 percent had newly started dialysis 30 days after surgery and 3.5 percent had started dialysis one year after surgery. In contrast, among patients with stages 1 and 2 chronic kidney disease, 0.7 percent had started dialysis after 30 days and 1.2 percent started dialysis after one year. Stage 3 patients represented 43 percent of the patient cohort.

"While patients with more severe chronic kidney disease do have a higher rate of both death and dialysis at 30 days and one year, we're encouraged that the absolute rate of new dialysis is relatively low in stage 3 patients," Hansen said. Until now, there has been no comprehensive data on the risk of dialysis for chronic kidney patients undergoing TAVR, he said. "While we have no way to predict any individual's outcome, we can tell patients that out of a cohort of patients similar to yourself, this is the likelihood of what can happen."

Patients with stage 4 or 5 disease have a greater risk of dialysis at one month and one year compared with stage 3 patients. The study found one-third of stage 4 patients died within one year of TAVR, with about one-sixth requiring dialysis. In stage 5 patients, more than one-third of patients required dialysis within 30 days, and almost two-thirds required it at one year.

In an editorial accompanying the study, Israel M. Barbash, MD, of the Sackler School of Medicine at Tel Aviv University, Israel, agreed that the findings provide a reassuring message. They point out that only patients with advanced suffer from high rates of dialysis (35 percent) at 30 days.

"In this context, it should be emphasized that this high-risk group represents a small minority of the entire TAVR population, less than 6 percent of the patients," he said.

Explore further: Study examines use, outcomes of valve replacement procedure performed for off-label indications

More information: JACC: Cardiovascular Interventions, DOI: 10.1016/j.jcin.2017.09.001

Related Stories

Study examines use, outcomes of valve replacement procedure performed for off-label indications

June 21, 2017
Approximately 1 in 10 transcatheter aortic valve replacement (TAVR) procedures in the U.S. were for an off-label indication, with similar 1-year mortality rates compared to on-label use, suggesting that TAVR may be a possible ...

'07 to '14 saw drop in proportion needing dialysis after TAVI

August 16, 2017
(HealthDay)—From 2007 to 2014 there was a decrease in the proportion of patients needing dialysis after transcatheter aortic valve implantation (TAVI), according to a study published online Aug. 2 in JACC: Cardiovascular ...

End-stage kidney disease study seeks to delay dialysis

September 1, 2017
Vanderbilt University Medical Center (VUMC) is studying the safety of a possible treatment for diabetic kidney disease that would delay or prevent the need for kidney replacement such as dialysis.

Dialysis patients may have faulty 'good' cholesterol

March 5, 2015
Kidney disease patients on dialysis often have impaired high-density lipoprotein (HDL) or "good" cholesterol, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). ...

1 in 7 Americans has kidney disease: CDC

June 9, 2017
(HealthDay)—Thirty million American adults have chronic kidney disease—but many don't know it.

Review IDs predictors of post-TAVR cerebrovascular events

August 9, 2016
(HealthDay)—For patients undergoing transcatheter aortic valve replacement (TAVR), predictors of cerebrovascular events (CVEs) include female sex, chronic kidney disease, new-onset atrial fibrillation, and enrollment date, ...

Recommended for you

'Good cholesterol' may not always be good

July 19, 2018
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) - also known as 'good cholesterol' - according to a study led by researchers in the University of Pittsburgh Graduate ...

Using adrenaline in cardiac arrests results in less than 1 percent more people leaving hospital alive

July 18, 2018
A clinical trial of the use of adrenaline in cardiac arrests has found that its use results in less than 1% more people leaving hospital alive—but almost doubles the risk of severe brain damage for survivors of cardiac ...

Omega 3 supplements have little or no heart or vascular health benefit: review

July 17, 2018
New evidence published today shows there is little or no effect of omega 3 supplements on our risk of experiencing heart disease, stroke or death.

Researchers discover new genes associated with heart function

July 17, 2018
A new study from an international research team, led by Dr. Yalda Jamshidi at St George's, University of London, has identified new genes associated with heart function and development.

Southern diet could be deadly for people with heart disease

July 12, 2018
People with a history of heart disease who eat a traditional Southern diet are more likely to die than those who follow a Mediterranean dietary pattern, according to new research.

Late-life high blood pressure may harm the brain, study says

July 11, 2018
Decades ago, hundreds of nuns and priests made an extraordinary decision: They agreed to donate their brains upon death to science, hoping to help solve mysteries about Alzheimer's and other diseases. Now, a study that used ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.